---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005046"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:48:42.675237+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics enters $14M registered direct offering at $1.04/share

## Summary
- Sale of 13,461,540 common shares at $1.04 each; gross proceeds of $14.0M.
- Broadwood Partners (affiliated with director Neal Bradsher) to buy 6,730,770 shares.
- Director Don M. Bailey to buy approximately 100,000 shares in the offering.
- Closing expected on or about February 8, 2024, subject to customary conditions.
- Proceeds to fund clinical trials, R&D, G&A, and working capital.

## SEC filing metadata
- accession: 0001493152-24-005046
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315224005046/0001493152-24-005046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315224005046/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005046
- JSON: https://secwatch.observer/filing/0001493152-24-005046.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005046.txt

## Key facts
- Material Agreements
  Lineage Cell Therapeutics, Inc. entered into purchase agreement with certain investors valued at $14.0 million (effective 2024-02-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: $14.0 million
  - Effective: 2024-02-06
  source text: On February 6, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”) entered into a stock purchase agreement (the “purchase agreement”) with certain investors relating to the purchase and sale in a registered direct offering of an aggregate of 13,461,540 common shares of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000149315224005046/0001493152-24-005046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.